KalVista Pharmaceuticals (KALV) Current Deferred Revenue (2014 - 2025)

KalVista Pharmaceuticals (KALV) reported Current Deferred Revenue of $11.4 million for Q3 2025, up 3.75% sequentially from $11.0 million in Q2 2025.

KalVista Pharmaceuticals (KALV) Current Deferred Revenue (2014 - 2025) Analysis & Trends

KalVista Pharmaceuticals (KALV) has 7 years of Current Deferred Revenue data on file, last reported at $11.4 million in Q3 2025.

For the quarter ending Q3 2025, Current Deferred Revenue changed N/A year-over-year to $11.4 million; the trailing twelve-month figure through Jul 2025 stood at $11.4 million (changed N/A YoY), and the FY2025 full-year result was $11.0 million, changed N/A from the prior year.
Current Deferred Revenue improved to $11.4 million in Q3 2025, from $11.0 million in the prior quarter.
In the past five years, Current Deferred Revenue ranged from a high of $11.4 million in Q3 2025 to a low of $11.0 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	KalVista Pharmaceuticals	1.36 Bn	1.36 Bn	49.41 Mn

Download Data